Literature DB >> 7531855

The putative anti-addictive drug ibogaine is a competitive inhibitor of [3H]MK-801 binding to the NMDA receptor complex.

P Popik1, R T Layer, P Skolnick.   

Abstract

Ibogaine is a putative anti-addictive drug with potential efficacy for the treatment of opiate, stimulant, and alcohol abuse. We now report ibogaine is a competitive inhibitor (Ki, 1.01 +/- 0.1 microM) of [3H]MK-801 binding to N-methyl-D-aspartate (NMDA) receptor coupled cation channels. Since MK-801 can attenuate the development of tolerance to morphine and alcohol as well as sensitization to stimulants in preclinical studies, the reported ability of ibogaine to modify drug-seeking behavior in man may be attributable to a blockade of NMDA receptor coupled cation channels.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7531855     DOI: 10.1007/bf02245000

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  16 in total

1.  Neuropharmacological studies on ibogaine, an indole alkaloid with central-stimulant properties.

Authors:  J A SCHNEIDER; E B SIGG
Journal:  Ann N Y Acad Sci       Date:  1957-03-14       Impact factor: 5.691

2.  Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801.

Authors:  K A Trujillo; H Akil
Journal:  Science       Date:  1991-01-04       Impact factor: 47.728

3.  Blockade of "reverse tolerance" to cocaine and amphetamine by MK-801.

Authors:  R Karler; L D Calder; I A Chaudhry; S A Turkanis
Journal:  Life Sci       Date:  1989       Impact factor: 5.037

4.  1-Aminocyclopropane carboxylic acid: a potent and selective ligand for the glycine modulatory site of the N-methyl-D-aspartate receptor complex.

Authors:  J C Marvizón; A H Lewin; P Skolnick
Journal:  J Neurochem       Date:  1989-03       Impact factor: 5.372

5.  Blockade of chronic tolerance to ethanol by the NMDA antagonist, (+)-MK-801.

Authors:  P H Wu; S J Mihic; J F Liu; A D Lê; H Kalant
Journal:  Eur J Pharmacol       Date:  1993-02-09       Impact factor: 4.432

6.  Ibogaine antagonizes cocaine-induced locomotor stimulation in mice.

Authors:  H Sershen; A Hashim; L Harsing; A Lajtha
Journal:  Life Sci       Date:  1992       Impact factor: 5.037

7.  Effects and aftereffects of ibogaine on morphine self-administration in rats.

Authors:  S D Glick; K Rossman; S Steindorf; I M Maisonneuve; J N Carlson
Journal:  Eur J Pharmacol       Date:  1991-04-03       Impact factor: 4.432

8.  Effect of D-cycloserine on rapid tolerance to ethanol.

Authors:  J M Khanna; H Kalant; G Shah; A Chau
Journal:  Pharmacol Biochem Behav       Date:  1993-08       Impact factor: 3.533

9.  L-NAME and MK-801 attenuate sensitization to the locomotor-stimulating effect of cocaine.

Authors:  C M Pudiak; M A Bozarth
Journal:  Life Sci       Date:  1993       Impact factor: 5.037

10.  Ibogaine reduces preference for cocaine consumption in C57BL/6By mice.

Authors:  H Sershen; A Hashim; A Lajtha
Journal:  Pharmacol Biochem Behav       Date:  1994-01       Impact factor: 3.533

View more
  8 in total

1.  Neuropharmacological characterization of local ibogaine effects on dopamine release.

Authors:  M S Reid; K Hsu; K H Souza; P A Broderick; S P Berger
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

2.  Pharmacological screen for activities of 12-hydroxyibogamine: a primary metabolite of the indole alkaloid ibogaine.

Authors:  J K Staley; Q Ouyang; J Pablo; W L Hearn; D D Flynn; R B Rothman; K C Rice; D C Mash
Journal:  Psychopharmacology (Berl)       Date:  1996-09       Impact factor: 4.530

3.  Long-lasting ibogaine protection against NMDA-induced convulsions in mice.

Authors:  M B Leal; D O de Souza; E Elisabetsky
Journal:  Neurochem Res       Date:  2000-08       Impact factor: 3.996

4.  Ibogaine and the dopaminergic response to nicotine.

Authors:  I M Maisonneuve; G L Mann; C R Deibel; S D Glick
Journal:  Psychopharmacology (Berl)       Date:  1997-02       Impact factor: 4.530

5.  In vitro and in vivo studies in rats with LY293558 suggest AMPA/kainate receptor blockade as a novel potential mechanism for the therapeutic treatment of anxiety disorders.

Authors:  Andrew Alt; Brianne Weiss; Ann Marie Ogden; Xia Li; Scott D Gleason; David O Calligaro; David Bleakman; Jeffrey M Witkin
Journal:  Psychopharmacology (Berl)       Date:  2006-02-10       Impact factor: 4.530

6.  Receptor binding profile suggests multiple mechanisms of action are responsible for ibogaine's putative anti-addictive activity.

Authors:  P M Sweetnam; J Lancaster; A Snowman; J L Collins; S Perschke; C Bauer; J Ferkany
Journal:  Psychopharmacology (Berl)       Date:  1995-04       Impact factor: 4.530

7.  EEG Gamma Band Alterations and REM-like Traits Underpin the Acute Effect of the Atypical Psychedelic Ibogaine in the Rat.

Authors:  Joaquín González; Matias Cavelli; Santiago Castro-Zaballa; Alejandra Mondino; Adriano B L Tort; Nicolás Rubido; Ignacio Carrera; Pablo Torterolo
Journal:  ACS Pharmacol Transl Sci       Date:  2021-01-11

8.  Memantine increases NMDA receptor level in the prefrontal cortex but fails to reverse apomorphine-induced conditioned place preference in rats.

Authors:  Ziphozethu Ndlazi; Oualid Abboussi; Musa Mabandla; Willie Daniels
Journal:  AIMS Neurosci       Date:  2018-09-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.